Education
About Us
Working with TipRanks
Follow Us
Harmony Biosciences Holdings (HRMY)
NASDAQ:HRMY
HRMY Stock Chart & Stats
$36.84
-$1.07(-3.04%)
At close: 4:00 PM EST
$36.84
-$1.07(-3.04%)
Day’s Range― - ―
52-Week Range$25.52 - $40.87
Previous CloseN/A
Volume87.33K
Average Volume (3M)574.96K
Market Cap
$2.17B
Enterprise Value$1.64B
Total Cash (Recent Filing)$672.58M
Total Debt (Recent Filing)$169.73M
Price to Earnings (P/E)11.6
Beta1.07
Next Earnings
Mar 03, 2026EPS Estimate
0.87Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.87
Shares Outstanding57,596,360
10 Day Avg. Volume665,691
30 Day Avg. Volume574,964
Financial Highlights & Ratios
PEG Ratio0.75
Price to Book (P/B)2.97
Price to Sales (P/S)2.74
P/FCF Ratio8.95
Enterprise Value/Market Cap0.76
Enterprise Value/Revenue1.99
Enterprise Value/Gross Profit2.56
Enterprise Value/Ebitda6.18
Forecast
1Y Price Target
$43.75Price Target Upside18.76% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering5
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Clinical EfficacyOpen‑label extension data from a Phase 3 study showed about a 50% median reduction in countable motor seizures for patients with Dravet syndrome with a favorable safety profile, supporting EPX‑100's potential competitive advantage in epilepsy.
Formulation InnovationBioequivalence results suggest the gastric‑retentive pitolisant can be initiated at the therapeutic dose without titration while maintaining efficacy, positioning a more tolerable, easier‑to‑use product versus the current formulation.
Regulatory FilingsAnalyst highlights an expected NDA submission for the pitolisant gastric‑retentive formulation in early 2026 after positive bioequivalence data, which could trigger a formal review and a clear regulatory milestone.
Bears Say
Clinical Trial TimingA delay in a key Phase 3 readout pushes back an important clinical milestone and could reduce near‑term upside visibility for the stock.
Development And Commercialization RiskClinical development and commercialization risks tied to pitolisant GR, pitolisant HD, and EPX‑100 mean negative trial results or launch challenges could materially impact expectations and valuation.
Market Access And External RisksExposure to competitor pressure, reimbursement and pricing uncertainty, and potential disruptions to trials from geopolitical events could limit product uptake and introduce execution risk.
Harmony Biosciences Holdings News
HRMY FAQ
What was Harmony Biosciences Holdings’s price range in the past 12 months?
Harmony Biosciences Holdings lowest stock price was $25.52 and its highest was $40.87 in the past 12 months.
What is Harmony Biosciences Holdings’s market cap?
Harmony Biosciences Holdings’s market cap is $2.17B.
When is Harmony Biosciences Holdings’s upcoming earnings report date?
Harmony Biosciences Holdings’s upcoming earnings report date is Mar 03, 2026 which is in 32 days.
How were Harmony Biosciences Holdings’s earnings last quarter?
Harmony Biosciences Holdings released its earnings results on Nov 04, 2025. The company reported $0.87 earnings per share for the quarter, beating the consensus estimate of $0.811 by $0.059.
Is Harmony Biosciences Holdings overvalued?
According to Wall Street analysts Harmony Biosciences Holdings’s price is currently Undervalued.
Does Harmony Biosciences Holdings pay dividends?
Harmony Biosciences Holdings does not currently pay dividends.
What is Harmony Biosciences Holdings’s EPS estimate?
Harmony Biosciences Holdings’s EPS estimate is 0.87.
How many shares outstanding does Harmony Biosciences Holdings have?
Harmony Biosciences Holdings has 57,596,360 shares outstanding.
What happened to Harmony Biosciences Holdings’s price movement after its last earnings report?
Harmony Biosciences Holdings reported an EPS of $0.87 in its last earnings report, beating expectations of $0.811. Following the earnings report the stock price went up 4.739%.
Which hedge fund is a major shareholder of Harmony Biosciences Holdings?
Currently, no hedge funds are holding shares in HRMY
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Harmony Biosciences Holdings Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$43.75 (18.76% Upside)
$43.75 (18.76% Upside)
Blogger Sentiment
Bullish
HRMY Sentiment 100%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 147.7K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 4.3%
Last 30 Days ▲ 9.9%
Last 30 Days ▲ 9.9%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-1.49%
12-Months-Change
Fundamentals
Return on Equity
25.93%
Trailing 12-Months
Asset Growth
30.18%
Trailing 12-Months
Company Description
Harmony Biosciences Holdings
Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, develops and commercializes therapies for patients with rare neurological disorders in the United States. Its product, WAKIX is a medication for the treatment of excessive daytime sleepiness in adult patients with narcolepsy. The company was formerly known as Harmony Biosciences II, Inc. and changed its name to Harmony Biosciences Holdings, Inc. in February 2020. Harmony Biosciences Holdings, Inc. was incorporated in 2017 and is based in Plymouth Meeting, Pennsylvania.
HRMY Company Deck
HRMY Earnings Call
Q3 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call reflected a strong performance in revenue growth and patient adds, showcasing the company's robust cash position and promising pipeline advancements. However, challenges were noted in the Fragile X syndrome study and increased operating expenses.View all HRMY earnings summariesHRMY Stock 12 Month Forecast
Average Price Target
$43.75
▲(18.76% Upside)
Technical Analysis
Ownership Overview
1.03% Insiders
20.76% Mutual Funds
0.13% Other Institutional Investors
51.26% Public Companies and Individual Investors